The Role of Anemia Management in Improving Outcomes for African-Americans with Chronic Kidney Disease (original) (raw)

1. Lakkis J, Weir MR. Pharmacological strategies for kidney function preservation: are there differences by ethnicity? Adv Ren Replace Ther. 2004;11:24–40. [PubMed] [Google Scholar]

2. United States Renal Data System: USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders, 2006.

3. Jamerson KA. Preventing chronic kidney disease in special populations. Am J Hypertens. 2005;18:106S–111S. [PubMed] [Google Scholar]

4. Prevalence of chronic kidney disease and associated risk factors: United States, 1999–2004. MMWR Morb Mortal Wkly Rep. 2007;56:161–165. [PubMed] [Google Scholar]

5. National Kidney Foundation-Kidney Early Evaluation Program KEEP annual data report 2006. Am J Kidney Dis. 2007;49:S1–S160. [Google Scholar]

6. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14:2902–2907. [PubMed] [Google Scholar]

7. Tareen N, Zadshir A, Martins D, Pan D, Nicholas S, Norris K. Chronic kidney disease in African American and Mexican American populations. Kidney Int. 2005;97(suppl):S137–S140. [PubMed] [Google Scholar]

8. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005;67:1483–1488. [PubMed] [Google Scholar]

9. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2004;43:836–845. [PubMed] [Google Scholar]

10. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003;18(suppl 2):ii7–ii12. [PubMed] [Google Scholar]

11. Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease. Dis Manag. 2007;10:37–45. [PubMed] [Google Scholar]

12. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood. 2005;106:740–745. [PMC free article] [PubMed] [Google Scholar]

13. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician. 2007;75:671–678. [PubMed] [Google Scholar]

14. Berns JS. Should all patients with chronic kidney disease receive an EPO-type drug? Cleve Clin J Med. 2006;73:298–300. [PubMed] [Google Scholar]

15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61. [PubMed] [Google Scholar]

16. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134. [PubMed] [Google Scholar]

17. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006;17:2293–2298. [PubMed] [Google Scholar]

18. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62:229–236. [PubMed] [Google Scholar]

19. Powe NR, Griffiths RI, Watson AJ, Anderson GF, de Lissovoy G, Greer JW, Herbert RJ, Milam RA, Whelton PK. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol. 1994;4:1455–1465. [PubMed] [Google Scholar]

20. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003;18(suppl 2):ii2–ii6. [PubMed] [Google Scholar]

21. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250–256. [PubMed] [Google Scholar]

22. Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J, Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract. 2005;101:c79–c86. [PubMed] [Google Scholar]

23. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69:560–564. [PubMed] [Google Scholar]

24. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10:2029–2043. [PubMed] [Google Scholar]

25. Ward HJ. Implications of recombinant erythropoietin therapy for renal transplantation. Am J Nephrol. 1990;10(suppl 2):44–47. discussion 48–52. [PubMed] [Google Scholar]

26. Sexauer CL, Matson JR. Anemia of chronic renal failure. Ann Clin Lab Sci. 1981;11:484–487. [PubMed] [Google Scholar]

27. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–S145. [PubMed] [Google Scholar]

28. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78. [PubMed] [Google Scholar]

29. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant. 2001;16(suppl 3):3–13. [PubMed] [Google Scholar]

30. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368:947–953. [PubMed] [Google Scholar]

31. Salem M. End-stage renal disease survival in blacks and whites. Am J Med Sci. 2002;323:100–101. [PubMed] [Google Scholar]

32. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68:914–924. [PubMed] [Google Scholar]

33. Powe NR. To have and have not: health and health care disparities in chronic kidney disease. Kidney Int. 2003;64:763–772. [PubMed] [Google Scholar]

34. Freedman BI. End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol Dial Transplant. 2002;17:198–200. [PubMed] [Google Scholar]

35. Adler S. Renal disease: environment, race, or genes? Ethn Dis. 2006;16(suppl 2):35–39. [PubMed] [Google Scholar]

36. Peralta CA, Ziv E, Katz R, Reiner A, Burchard EG, Fried L, Kwok PY, Psaty B, Shlipak M. African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis. J Am Soc Nephrol. 2006;17:3491–3496. [PubMed] [Google Scholar]

37. Boone CA. End-stage renal disease in African-Americans. Nephrol Nurs J. 2000;27:597–600. [PubMed] [Google Scholar]

38. Price DA, Owen WF., Jr African-Americans on maintenance dialysis: a review of racial differences in incidence, treatment, and survival. Adv Ren Replace Ther. 1997;4:3–12. [PubMed] [Google Scholar]

39. Young CJ, Kew C. Health disparities in transplantation: focus on the complexity and challenge of renal transplantation in African Americans. Med Clin North Am. 2005;89:1003–1031. [PubMed] [Google Scholar]

40. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG. Management of high blood pressure in African Americans: consensus statement of the hypertension in African Americans working group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541. [PubMed] [Google Scholar]

41. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165:947–953. [PubMed] [Google Scholar]

42. Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int. 2004;92(suppl):S102–S104. [PubMed] [Google Scholar]

43. Toto RD. Lessons from the African-American study of kidney disease and hypertension: an update. Curr Hypertens Rep. 2006;8:409–412. [PubMed] [Google Scholar]

44. Martins D, Tareen N, Zadshir A, Pan D, Vargas R, Nissenson A, Norris K. The association of poverty with the prevalence of albuminuria: data from the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis. 2006;47:965–971. [PMC free article] [PubMed] [Google Scholar]

45. Schreuder MF, Nauta J. Prenatal programming of nephron number and blood pressure. Kidney Int. 2007;72:265–268. [PubMed] [Google Scholar]

46. Grella PV. Low birth weight and early life origins of adult disease: insulin resistance and type 2 diabetes. Clin Exp Obstet Gynecol. 2007;34:9–13. [PubMed] [Google Scholar]

47. Haas M. Hypertension, race, and glomeruli: more than simply a numbers game. Kidney Int. 2006;69:640–642. [PubMed] [Google Scholar]

48. Hughson MD, Douglas-Denton R, Bertram JF, Hoy WE. Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. Kidney Int. 2006;69:671–678. [PubMed] [Google Scholar]

49. Neal L, Greene EL. Pathophysiology of chronic progressive renal disease in the African American patient with hypertension. Am J Med Sci. 2002;323:72–77. [PubMed] [Google Scholar]

50. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088–1096. [PubMed] [Google Scholar]

51. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10:49S–55S. [PubMed] [Google Scholar]

52. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. The MRFIT research group. JAMA. 1992;268:3085–3091. [PubMed] [Google Scholar]

53. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT., Jr A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American study of kidney disease and hypertension. J Am Soc Nephrol. 2004;15:3175–3183. [PubMed] [Google Scholar]

54. Appel LJ, Middleton J, Miller ER, 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14:S166–S172. [PubMed] [Google Scholar]

55. Kaperonis N, Bakris G. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003;12:79–84. [PubMed] [Google Scholar]

56. Wright JT, Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595–1608. [PubMed] [Google Scholar]

57. Ferdinand KC. Recommendations for the management of special populations: Racial and ethnic populations. Am J Hypertens. 2003;16:50S–54S. [PubMed] [Google Scholar]

58. Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American study of kidney disease and hypertension (aask) trial. Kidney Int. 2003;91(suppl):S74–S76. [PubMed] [Google Scholar]

59. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728. [PubMed] [Google Scholar]

60. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ. Baseline predictors of renal disease progression in the African American study of hypertension and kidney disease. J Am Soc Nephrol. 2006;17:2928–2936. [PMC free article] [PubMed] [Google Scholar]

61. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–524. [PubMed] [Google Scholar]

62. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci. 2002;323:65–71. [PubMed] [Google Scholar]

63. Crook ED. Diabetic renal disease in African Americans. Am J Med Sci. 2002;323:78–84. [PubMed] [Google Scholar]

64. Martins D, Norris K. Combating diabetic nephropathy with drug therapy. Curr Diab Rep. 2001;1:148–156. [PubMed] [Google Scholar]

65. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–1510. [PubMed] [Google Scholar]

66. Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis. 2006;48:537–545. [PubMed] [Google Scholar]

67. McCullough PA, Lepor NE. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med. 2005;6:1–10. [PubMed] [Google Scholar]

68. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med. 2006;73:289–297. [PubMed] [Google Scholar]

69. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192. [PubMed] [Google Scholar]

70. East MA, Jollis JG, Nelson CL, Marks D, Peterson ED. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? J Am Coll Cardiol. 2003;41:949–954. [PubMed] [Google Scholar]

71. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dl. Kidney Int. 2005;68:788–795. [PubMed] [Google Scholar]

72. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005 CD003266. [PubMed] [Google Scholar]

73. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530. [PubMed] [Google Scholar]

74. Dean BB, Dylan M, Gano A, Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin. 2005;21:981–987. [PubMed] [Google Scholar]

75. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307–312. [PubMed] [Google Scholar]

76. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753–760. [PubMed] [Google Scholar]

77. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001;37:348–355. [PubMed] [Google Scholar]

78. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. [PubMed] [Google Scholar]

79. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. [PubMed] [Google Scholar]

80. Food and Drug Administration: Information for healthcare professionals: Erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa), 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm

81. Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64:499–509. [PubMed] [Google Scholar]

82. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–1215. [PubMed] [Google Scholar]

83. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646. [PubMed] [Google Scholar]

84. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D. Continuous erythropoietin receptor activator (CERA) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006;60:1687–1696. [PubMed] [Google Scholar]

85. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC. The continuous erythropoietin receptor activator (CERA) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67:306–317. [PubMed] [Google Scholar]

86. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW. Preclinical evaluation of hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34:1303–1311. [PubMed] [Google Scholar]

87. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM. Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–1834. [PubMed] [Google Scholar]

88. Rastogi A, Nissenson AR. New approaches to the management of anemia of chronic kidney disease: beyond Epogen and Infed. Kidney Int. 2006;70(suppl):S14–S16. [Google Scholar]

90. Gadegbeku C, Freeman M, Agodoa L. Racial disparities in renal replacement therapy. J Natl Med Assoc. 2002;94:45S–54S. [PMC free article] [PubMed] [Google Scholar]

91. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF., Jr Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol. 2002;13:1288–1295. [PubMed] [Google Scholar]

92. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF., Jr Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: results from the 1997 ESRD core indicators project. Am J Kidney Dis. 1999;34:721–730. [PubMed] [Google Scholar]

93. Ifudu O. Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant. 2002;17(suppl 5):38–41. [PubMed] [Google Scholar]

94. Jones-Burton C, Seliger SL, Brown J, Stackiewicz L, Hsu VD, Fink JC. Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Nephrol Dial Transplant. 2005;20:2739–2745. [PubMed] [Google Scholar]

95. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ. Trends in anemia at initiation of dialysis in the United States. Kidney Int. 2001;60:1875–1884. [PubMed] [Google Scholar]

96. Volkova N, McClellan W, Soucie JM, Schoolwerth A. Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients. Nephrol Dial Transplant. 2006;21:2202–2209. [PubMed] [Google Scholar]

97. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int. 2006;70(suppl):S13–S18. [PubMed] [Google Scholar]

98. Heme Iron Polypeptide: A radically different oral iron. Nephrol News Issues. 2002;16:39–41. [PubMed] [Google Scholar]

99. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64:113–123. [PubMed] [Google Scholar]

100. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005;20:2146–2152. [PubMed] [Google Scholar]

101. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327–334. [PubMed] [Google Scholar]

102. Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from Simplify the Treatment of Anemia with Aranesp (STAAR) Am J Nephrol. 2006;26:149–156. [PubMed] [Google Scholar]

103. Reddan DN, Frankenfield DL, Klassen PS, Coladonato JA, Szczech L, Johnson CA, Besarab A, Rocco M, McClellan W, Wish J, Owen WF., Jr Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant. 2003;18:147–152. [PubMed] [Google Scholar]

104. Rodriguez RA, Sen S, Mehta K, Moody- Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med. 2007;146:493–501. [PubMed] [Google Scholar]

105. Nzerue CM, Demissochew H, Tucker JK. Race and kidney disease: Role of social and environmental factors. J Natl Med Assoc. 2002;94:28S–38S. [PMC free article] [PubMed] [Google Scholar]

106. Ifudu O, Chan E, Paul H, Mayers JD, Cohen LS, Brezsnyak WF, Herman AI, Avram MM, Friedman EA. Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients. ASAIO J. 1996;42:146–149. [PubMed] [Google Scholar]

107. Foley RN, Li Q, Gilbertson DT, Collins AJ, Dunning SC. Poster F-PO375, presented November 17, 2006. San Diego: American Society of Nephrology Annual Meeting; 2006. Association between missed dialysis sessions and hemoglobin variability in the US. [Google Scholar]

108. Locatelli F, Del Vecchio L, Pozzoni P, Andrulli S. Dialysis adequacy and response to erythropoiesis-stimulating agents: what is the evidence base? Semin Nephrol. 2006;26:269–274. [PubMed] [Google Scholar]

109. Horl WH. Anemia and its treatment in peritoneal dialysis patients. Wien Klin Wochenschr. 2005;117(suppl 6):69–72. [PubMed] [Google Scholar]

110. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol. 2004;15:174–179. [PubMed] [Google Scholar]

111. Macdougall IC. How to optimise anaemia therapy in peritoneal dialysis patients. Contrib Nephrol. vol 150. Basel: Karger; 2006. pp. 202–213. vol 150. [PubMed] [Google Scholar]

112. Epogen® (US prescribing information). Thousand Oaks, Amgen, Inc., 2007.

113. Aranesp® (US prescribing information) Thousand Oaks: Amgen, Inc.; 2007. [Google Scholar]

114. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590. [PubMed] [Google Scholar]

115. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–961. [PubMed] [Google Scholar]

116. Hostetter TH. Research opportunities for reducing racial disparities in kidney disease. Adv Ren Replace Ther. 2004;11:59–65. [PubMed] [Google Scholar]

117. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266. [PubMed] [Google Scholar]

118. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, Wallace S, Macleod A. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2005 CD003895. [PubMed] [Google Scholar]

119. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898–903. [PubMed] [Google Scholar]

120. Macdougall IC, Walker R, Provenzano R; ARCTOS Study Investigators: C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. Poster Sa-PO208, presented November 18, 2006. San Diego, American Society of Nephrology 39th Annual Meeting, 2006.

121. Klinger M, Arias M, Vargemezis V; AMICUS Study Investigators: C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis. Poster Sa-PO212, presented November 18, 2006. San Diego, American Society of Nephrology 39th Annual Meeting, 2006.

122. Fishbane S, Levin NW, Mann JFE, MAXIMA Study Investigators: IV CERA (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1–3 times per week in patients with CKD on dialysis. Poster Sa-PO205, presented November 18, 2006. San Diego, American Society of Nephrology 39th Annual Meeting, 2006.

123. Canaud B, Braun J, Locatelli F; STRIATA Study Investigators: C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable hemoglobin (Hb) levels in patients with chronic kidney disease on dialysis. 43rd European Renal Association-European Dialysis and Transplant Association Congress, Glasgow, 2006.

124. O'Mara NB, Kapoian T. Continuous erythropoiesis receptor activator (CERA): an erythropoiesis-stimulating agent for the treatment of anemia in patients with chronic kidney disease. Formulary. 2007;42:233–244. [Google Scholar]

125. United Kingdom Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703–713. [PMC free article] [PubMed] [Google Scholar]

126. HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. [PubMed] [Google Scholar]

127. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, de Alvaro F. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207. [PubMed] [Google Scholar]

128. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr. 1993;122:1417–1424. [PubMed] [Google Scholar]

129. McLaren CE, Li K, Gordeuk VR, Hasselblad V, McLaren GD. Relationship between transferrin saturation and iron stores in the African American and US Caucasian populations: analysis of data from the third National Health and Nutrition Examination Survey. Blood. 2001;98:2345–2351. [PubMed] [Google Scholar]

130. Schechter GP. Hemoglobin levels in African-Americans. Blood. 2006;107:2208–2209. [PubMed] [Google Scholar]

131. Weisbord SD, Fried LF, Mor MK, Resnick AL, Kimmel PL, Palevsky PM, Fine MJ. Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy. J Natl Med Assoc. 2007;99:1218–1226. [PMC free article] [PubMed] [Google Scholar]

132. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ: Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant. 2007;Epub ahead of print. [PubMed]